INLB

Item 9 Labs Corp. [INLB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

INLB Stock Summary

In the News

11:53 28 Mar 2024 INLB

Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2022 Results - Earnings Call Transcript

Item 9 Labs Corp. (OTCQX:INLB) Q3 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Jason Assad [Abrupt Start] Joining me on today's call is our Chief Executive Officer, Andrew Bowden and our Chief Financial Officer, Bobby Mikkelson. Shortly before this call, we filed our Form 10-Q, a copy of which is available on the company's website at item9labscorp.com.

09:04 28 Mar 2024 INLB

Item 9 Labs Corp. (INLB) Reports Q3 Loss, Misses Revenue Estimates

Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -100% and 29.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

10:36 28 Mar 2024 INLB

Item 9 Labs Corp. to Host Third Quarter Fiscal Year 2022 Earnings Call on August 16 at 8:30 a.m. ET

PHOENIX , Aug. 3, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that it will host a conference call on Tuesday August 16, 2022, to share financial results for the third quarter of fiscal year 2022, which ended June 30, 2022. The 10Q will be filed on Monday, August 15, 2022.

11:25 28 Mar 2024 INLB

Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q2 2022 Results - Earnings Call Transcript

Item 9 Labs Corp. (OTCQX:INLB) Q2 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Conference Call Participants Jason Assad Hello, this is Jason Assad, Investor Relations with Item 9 Labs. Good afternoon, and welcome to Item 9 Labs Fiscal Q2 2022 Results Conference Call for the three months ended March 31, 2022.

08:18 28 Mar 2024 INLB

Item 9 Labs Corp. (INLB) Reports Q2 Loss, Lags Revenue Estimates

Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -33.33% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

09:17 28 Mar 2024 INLB

Item 9 Labs Corp. to Present at Leading Investor Conferences in April

Vertically Integrated Cannabis Dispensary Franchisor and Operator to Share Recent Positive Momentum for Accelerated National Growth in 2022 PHOENIX , April 5, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company") – a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products – announced today that the Company's executive team will be participating in multiple investor events in April. These events include: Noble Capital Markets' 18th Annual Small & Microcap Investor Conference (NobleCon18), Sequire's Cannabis & Psychedelic Virtual Conference and Benzinga's Spring Cannabis Capital Conference.

10:49 28 Mar 2024 INLB

Unity Rd.'s Chief Franchise Officer to Present at International Franchise Association's 2022 Convention

PHOENIX, Feb. 21, 2022 /PRNewswire/ -- Unity Rd., the first true vertically integrated cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), continues to establish itself as a rising trailblazer in franchising.

05:33 28 Mar 2024 INLB

Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q1 2022 Results - Earnings Call Transcript

Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q1 2022 Results - Earnings Call Transcript

03:48 28 Mar 2024 INLB

Unity Rd.'s VP of Communications to Present at YoungConference

PHOENIX, Jan. 25, 2022 /PRNewswire/ -- Unity Rd., the cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), continues to solidify their position as industry trailblazers.

05:08 28 Mar 2024 INLB

Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript

Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript

INLB Financial details

Company Rating
Buy
Market Cap
30.71K
Income
-31.05M
Revenue
19.69M
Book val./share
0.53
Cash/share
0
Dividend
-
Dividend %
-
Employees
97
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
0
Forward P/E
-
PEG
-
P/S
0.01
P/B
-
P/C
-
P/FCF
-0.05
Quick Ratio
0.02
Current Ratio
0.06
Debt / Equity
0.65
LT Debt / Equity
0
-
-
EPS (TTM)
-0.33
EPS next Y
-
EPS next Q
1.57
EPS this Y
57.14%
EPS next Y
-
EPS next 5Y
-75.5%
EPS last 5Y
7.49%
Revenue last 5Y
73.72%
Revenue Q/Q
-11.31%
EPS Q/Q
78.04%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-53%
ROC
-0.19%
Gross Margin
50%
Oper. Margin
-52%
Profit Margin
-158%
Payout
-
Shs Outstand
102.36M
Shs Float
76.45M
-
-
-
-
Target Price
-
52W Range
2.0E-4-0.14
52W High
-
52W Low
-
RSI
42.62
Rel Volume
3.44
Avg Volume
16.05M
Volume
55.16M
Perf Week
-37.5%
Perf Month
-50%
Perf Quarter
-97.92%
Perf Half Y
-98.53%
-
-
-
-
Beta
0.792
-
-
Volatility
0%, 0%
Prev Close
-28.57%
Price
0.00025
Change
-37.5%

INLB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-09-30

Metric History 2018-09-302019-09-302020-09-302021-09-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.50.080.130.280.23
Net income per share
-0.23-0.17-0.2-0.21-0.33
Operating cash flow per share
-0.36-0.04-0.02-0.08-0.02
Free cash flow per share
-0.55-0.14-0.03-0.11-0.08
Cash per share
0.06000.020
Book value per share
0.960.120.131.110.66
Tangible book value per share
0.960.07-0.010.12-0.09
Share holders equity per share
0.960.120.131.110.66
Interest debt per share
0.010.130.240.340.36
Market cap
301.22K171.67M92.43M123.86M37.28M
Enterprise value
151.95K176.42M100.23M143.34M65.04M
P/E ratio
-0.47-16.15-7.52-7.65-1.2
Price to sales ratio
0.2234.7911.385.651.71
POCF ratio
-0.31-71.73-80.98-20.68-16.54
PFCF ratio
-0.2-19.4-59.73-15.05-4.83
P/B Ratio
0.1223.0111.531.440.6
PTB ratio
0.1223.0111.531.440.6
EV to sales
0.1135.7612.346.532.99
Enterprise value over EBITDA
-0.25-55.64-23.06-32.95-5.81
EV to operating cash flow
-0.16-73.71-87.81-23.93-28.85
EV to free cash flow
-0.1-19.93-64.77-17.41-8.43
Earnings yield
-2.13-0.06-0.13-0.13-0.84
Free cash flow yield
-5.04-0.05-0.02-0.07-0.21
Debt to equity
0.0110.980.240.45
Debt to assets
0.010.520.380.180.25
Net debt to EBITDA
0.24-1.5-1.79-4.48-2.48
Current ratio
1.930.420.280.710.09
Interest coverage
-347.63-12.79-0.77-1.06-2.05
Income quality
1.520.240.090.550.07
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.290.830.680.450.78
Research and developement to revenue
00000
Intangibles to total assets
00.20.430.660.63
Capex to operating cash flow
0.562.70.360.372.42
Capex to revenue
-0.39-1.31-0.05-0.1-0.25
Capex to depreciation
-10.9-9.55-0.41-1.78-2.84
Stock based compensation to revenue
00.050.040.080.14
Graham number
2.250.690.762.272.21
ROIC
-0.27-0.31-0.33-0.08-0.14
Return on tangible assets
-0.18-0.92-1.04-0.4-0.76
Graham Net
-0.01-0.11-0.2-0.32-0.5
Working capital
834.38K-4.17M-7.4M-4.39M-37.03M
Tangible asset value
2.62M4.38M-866.26K9.38M-8.03M
Net current asset value
834.38K-4.17M-9.76M-20.11M-45.27M
Invested capital
0.0110.980.240.45
Average receivables
465.26K683.77K394.81K900.44K1.02M
Average payables
1.21M898.53K1.53M2.87M5.09M
Average inventory
3.5K90K130K3.24M4.43M
Days sales outstanding
246.9632.3315.8524.19.84
Days payables outstanding
258.31153.72149.54102.99162.27
Days of inventory on hand
025.76.05175.0862.27
Receivables turnover
1.4811.2923.0315.1537.11
Payables turnover
1.412.372.443.542.25
Inventory turnover
014.260.322.085.86
ROE
-0.25-1.43-1.53-0.19-0.5
Capex per share
-0.2-0.1-0.01-0.03-0.06

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q3

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.050.040.050.060.05
Net income per share
-0.06-0.2-0.03-0.03-0.06
Operating cash flow per share
-0.020-0.0100
Free cash flow per share
-0.02-0.02-0.0100
Cash per share
00000
Book value per share
0.820.670.610.570.53
Tangible book value per share
0.01-0.09-0.09-0.12-0.17
Share holders equity per share
0.820.670.610.570.53
Interest debt per share
0.330.330.350.360.38
Market cap
76.93M36.65M12.39M10.11M5.27M
Enterprise value
106.75M64.41M44.96M43.88M39.38M
P/E ratio
-3.51-0.5-0.95-0.74-0.22
Price to sales ratio
15.69.162.481.781.05
POCF ratio
-32.19-153.87-9.2933.435.11
PFCF ratio
-37.1-22.25-9.2433.2460.38
P/B Ratio
0.980.590.210.180.1
PTB ratio
0.980.590.210.180.1
EV to sales
21.6516.18.997.757.84
Enterprise value over EBITDA
-31.88-4.16-46.91-51.41-16.67
EV to operating cash flow
-44.67-270.4-33.69145.02262.31
EV to free cash flow
-51.48-39.11-33.52144.31451.16
Earnings yield
-0.07-0.5-0.26-0.34-1.12
Free cash flow yield
-0.03-0.04-0.110.030.02
Debt to equity
0.390.450.540.590.65
Debt to assets
0.250.250.280.30.31
Net debt to EBITDA
-8.9-1.79-33.98-39.57-14.44
Current ratio
0.140.090.060.080.06
Interest coverage
-2.37-1.76-0.86-0.62-1
Income quality
0.440.010.41-0.09-0.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.751.730.610.590.6
Research and developement to revenue
00000
Intangibles to total assets
0.640.630.610.610.62
Capex to operating cash flow
-0.135.910.010-0.42
Capex to revenue
0.06-0.3500-0.01
Capex to depreciation
0.63-2.75-0.020-0.15
Stock based compensation to revenue
0.190.120.210.080.17
Graham number
1.021.730.670.660.85
ROIC
-0.04-0.05-0.02-0.01-0.03
Return on tangible assets
-0.13-0.45-0.07-0.08-0.14
Graham Net
-0.41-0.51-0.53-0.54-0.58
Working capital
-33.78M-37.03M-43.73M-43.45M-55.47M
Tangible asset value
1.05M-8.03M-9.32M-11.7M-16.27M
Net current asset value
-36.33M-45.27M-51.47M-52.76M-56.02M
Invested capital
0.390.450.540.590.65
Average receivables
884.25K588.89K594.1K598.73K781.78K
Average payables
5.67M6.12M6.4M6.65M6.89M
Average inventory
4.48M3.3M2.2M2.29M2.27M
Days sales outstanding
10.813.1910.839.4617.35
Days payables outstanding
156.75172.24241.01320.24279.87
Days of inventory on hand
111.2666.0973.2122.277.54
Receivables turnover
8.346.838.319.515.19
Payables turnover
0.570.520.370.280.32
Inventory turnover
0.811.361.230.741.16
ROE
-0.07-0.3-0.05-0.06-0.11
Capex per share
0-0.02000

INLB Frequently Asked Questions

What is Item 9 Labs Corp. stock symbol ?

Item 9 Labs Corp. is a US stock , located in Phoenix of Az and trading under the symbol INLB

What is Item 9 Labs Corp. stock quote today ?

Item 9 Labs Corp. stock price is $0.00025 today.

Is Item 9 Labs Corp. stock public?

Yes, Item 9 Labs Corp. is a publicly traded company.

Something similar

Top by Market Cap
Same Price Range
Similar Market Cap